Feed IDXX
ID

IDEXX Laboratories

IDXX · NASDAQ

$515.30 +1.38% (+$7.00)
1M -7.90%
Market Cap $40.6B
P/E Ratio 35.67x
Div. Yield -
ROE 71.96%

Bulios Fair Price

$315.27

38.8% downside

Current Price

$515.3

Undervalued Fair Value Overvalued

According to Bulios Fair Price, IDXX is currently overvalued relative to its market price. How does it work?

Bulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?

Piotroski F-Score Strong
9/9
Valuation
18 /100
Expensive
P/E 35.67x
EV/EBITDA 25.68x
PEG 1.99x
Growth
82 /100
Growing
EPS growth 17.66%
Rev. growth 8.52%
Book val. growth 38.16%
Profitability
100 /100
Strong
Gross margin 62.45%
Net margin 25.03%
FCF margin 27.47%
Quality
100 /100
Excellent
ROIC 40.94%
ROE 71.96%
Asset turnover 1.32x
Debt
83 /100
Low
Debt/Equity 0.68x
Current ratio 1.17x
Net debt/EBITDA 0.56x
Stability
83 /100
Stable
Beta 1.54x
Rev. volatility 1.99%
Profitable years 6

Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more

Ask StockBot about IDXX
Online

About the company

IDEXX Laboratories, Inc. (IDXX) is an American company specializing in the development and manufacturing of diagnostic tests for veterinary care. With a portfolio of innovative diagnostic products, laboratory tests, and software solutions, IDEXX Laboratories provides essential support to veterinarians and veterinary laboratories. The company is known for its technologically advanced methods of animal diagnostics, enabling rapid and accurate determination of diseases and the overall health status of animals.

Sector

Healthcare

Industry

Medical - Diagnostics & Research

CEO

Michael Erickson

Employees

11,000

Headquarters

Westbrook

Upcoming events

02 NOV

Earnings

Upcoming earnings report

41d

We use essential cookies to run the website and optional analytics cookies to measure usage. See our Privacy Policy.